Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

Rhea-AI Summary

Pulse Biosciences' nsPFA technology to be featured at Global EP Summit 2023

Positive

• Pulse Biosciences' nsPFA technology offers a time advantage and simpler procedure for atrial fibrillation treatment

Negative

• None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29^th to 30^th, 2023.

“I believe Pulse Biosciences’ nsPFA circumferential catheter system represents a novel and highly differentiated solution for the treatment of atrial fibrillation by electrophysiologists. Consistently performing circumferential ablations of targeted pulmonary veins in a single shot, in approximately 5 seconds with nsPFA, not only represents a significant time advantage, but also a simpler procedure that could lead to improved patient outcomes,” said Dr. Usman Siddiqui, Chief of Electrophysiology at Advent Health, Director of EP at Advent/Nicholson Center, Associate Professor of Medicine University of Central Florida. “I look forward to detailing both the utility of the novel energy modality and its potential impact on the treatment of AF with fellow EPs at the Global EP Summit.”

Presentation Details:
Next Generation PFA
Dr. Usman R. Siddiqui
September 29, 2023 from 8:20 am – 8:30 am ET

During this presentation, Dr. Usman Siddiqui will be discussing Pulse Biosciences’ nsPFA technology and catheter system.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230929523434/en/

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.